 A 2006 court case, "Abigail Alliance v. von Eschenbach", would have forced radical changes in FDA regulation of unapproved drugs.The Abigail Alliance argued that the FDA must license drugs for use by terminally ill patients with "desperate diagnoses," after they have completed Phase I testing.The case won an initial appeal in May 2006, but that decision was reversed by a March 2007 rehearing.